APO Research
Talk to an analyst

APO RESEARCH · REPORT

Atypical Antipsychotic Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Atypical Antipsychotic Drugs Market Outlook and Growth Opportunities 2026

22 December 2025198 pages

Choose your research edition.

Industry ResearchAtypical Antipsychotic Drugs Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Atypical Antipsychotic Drugs Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Atypical Antipsychotic Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Atypical Antipsychotic Drugs Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Atypical Antipsychotic Drugs Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Atypical Antipsychotic Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Atypical Antipsychotic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Atypical Antipsychotic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Atypical Antipsychotic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Atypical Antipsychotic Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Atypical Antipsychotic Drugs market include Sun Pharmaceutical Industries, Johnson and Johnson, Qilu Pharmaceutical, Novartis AG, Eil Lilly and Company, Pfizer, GlaxoSmithKline, AstraZeneca and Sumitomo Dainippon Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Atypical Antipsychotic Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Atypical Antipsychotic Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Atypical Antipsychotic Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Atypical Antipsychotic Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Atypical Antipsychotic Drugs Segment by Company

Sun Pharmaceutical Industries

Johnson and Johnson

Qilu Pharmaceutical

Novartis AG

Eil Lilly and Company

Pfizer

GlaxoSmithKline

AstraZeneca

Sumitomo Dainippon Pharma

Sanis Health

Cardinal Health

Bristol-Myers Squibb Company

Allergan

Atypical Antipsychotic Drugs Segment by Type

Olanzapine

Quetiapine

Risperidone

Ziprasidone

Others

Atypical Antipsychotic Drugs Segment by Application

Schizoaffective Disorder

Schizophrenia

Bipolar I Disorder

Major Depressive Disorder (MDD)

Atypical Antipsychotic Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Atypical Antipsychotic Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Atypical Antipsychotic Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Atypical Antipsychotic Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Atypical Antipsychotic Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Atypical Antipsychotic Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Atypical Antipsychotic Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Atypical Antipsychotic Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Atypical Antipsychotic Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Atypical Antipsychotic Drugs industry.

Chapter 3: Detailed analysis of Atypical Antipsychotic Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Atypical Antipsychotic Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Atypical Antipsychotic Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Atypical Antipsychotic Drugs Industry Trends Table 2. Atypical Antipsychotic Drugs Industry Drivers Table 3. Atypical Antipsychotic Drugs Industry Opportunities and Challenges Table 4. Atypical Antipsychotic Drugs Industry Restraints Table 5. Global Atypical Antipsychotic Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Atypical Antipsychotic Drugs Revenue Share by Company (2021-2026) Table 7. Global Atypical Antipsychotic Drugs Sales Volume by Company (k units) & (2021-2026) Table 8. Global Atypical Antipsychotic Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Atypical Antipsychotic Drugs Average Price (US$/unit) of Company (2021-2026) Table 10. Global Atypical Antipsychotic Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Atypical Antipsychotic Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Atypical Antipsychotic Drugs Company, Product Type & Application Table 13. Global Atypical Antipsychotic Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Atypical Antipsychotic Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Olanzapine Table 18. Significant Companies of Quetiapine Table 19. Significant Companies of Risperidone Table 20. Significant Companies of Ziprasidone Table 21. Significant Companies of Others Table 22. Global Atypical Antipsychotic Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 23. Global Atypical Antipsychotic Drugs Sales Volume by Type (2021-2026) & (k units) Table 24. Global Atypical Antipsychotic Drugs Sales Volume by Type (2027-2032) & (k units) Table 25. Global Atypical Antipsychotic Drugs Sales Volume Share by Type (2021-2026) Table 26. Global Atypical Antipsychotic Drugs Sales Volume Share by Type (2027-2032) Table 27. Global Atypical Antipsychotic Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Atypical Antipsychotic Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Atypical Antipsychotic Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Atypical Antipsychotic Drugs Sales Value Share by Type (2021-2026) Table 31. Global Atypical Antipsychotic Drugs Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Schizoaffective Disorder Table 33. Significant Companies of Schizophrenia Table 34. Significant Companies of Bipolar I Disorder Table 35. Significant Companies of Major Depressive Disorder (MDD) Table 36. Global Atypical Antipsychotic Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 37. Global Atypical Antipsychotic Drugs Sales Volume by Application (2021-2026) & (k units) Table 38. Global Atypical Antipsychotic Drugs Sales Volume by Application (2027-2032) & (k units) Table 39. Global Atypical Antipsychotic Drugs Sales Volume Share by Application (2021-2026) Table 40. Global Atypical Antipsychotic Drugs Sales Volume Share by Application (2027-2032) Table 41. Global Atypical Antipsychotic Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Atypical Antipsychotic Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global Atypical Antipsychotic Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global Atypical Antipsychotic Drugs Sales Value Share by Application (2021-2026) Table 45. Global Atypical Antipsychotic Drugs Sales Value Share by Application (2027-2032) Table 46. Global Atypical Antipsychotic Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 47. Global Atypical Antipsychotic Drugs Sales by Region (2021-2026) & (k units) Table 48. Global Atypical Antipsychotic Drugs Sales Market Share by Region (2021-2026) Table 49. Global Atypical Antipsychotic Drugs Sales by Region (2027-2032) & (k units) Table 50. Global Atypical Antipsychotic Drugs Sales Market Share by Region (2027-2032) Table 51. Global Atypical Antipsychotic Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Atypical Antipsychotic Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global Atypical Antipsychotic Drugs Sales Value Share by Region (2021-2026) Table 54. Global Atypical Antipsychotic Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global Atypical Antipsychotic Drugs Sales Value Share by Region (2027-2032) Table 56. Global Atypical Antipsychotic Drugs Market Average Price (US$/unit) by Region (2021-2026) Table 57. Global Atypical Antipsychotic Drugs Market Average Price (US$/unit) by Region (2027-2032) Table 58. Global Atypical Antipsychotic Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 59. Global Atypical Antipsychotic Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Atypical Antipsychotic Drugs Sales by Country (2021-2026) & (k units) Table 61. Global Atypical Antipsychotic Drugs Sales Market Share by Country (2021-2026) Table 62. Global Atypical Antipsychotic Drugs Sales by Country (2027-2032) & (k units) Table 63. Global Atypical Antipsychotic Drugs Sales Market Share by Country (2027-2032) Table 64. Global Atypical Antipsychotic Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global Atypical Antipsychotic Drugs Sales Value Market Share by Country (2021-2026) Table 66. Global Atypical Antipsychotic Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global Atypical Antipsychotic Drugs Sales Value Market Share by Country (2027-2032) Table 68. Sun Pharmaceutical Industries Company Information Table 69. Sun Pharmaceutical Industries Business Overview Table 70. Sun Pharmaceutical Industries Atypical Antipsychotic Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Sun Pharmaceutical Industries Atypical Antipsychotic Drugs Product Portfolio Table 72. Sun Pharmaceutical Industries Recent Development Table 73. Johnson and Johnson Company Information Table 74. Johnson and Johnson Business Overview Table 75. Johnson and Johnson Atypical Antipsychotic Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Johnson and Johnson Atypical Antipsychotic Drugs Product Portfolio Table 77. Johnson and Johnson Recent Development Table 78. Qilu Pharmaceutical Company Information Table 79. Qilu Pharmaceutical Business Overview Table 80. Qilu Pharmaceutical Atypical Antipsychotic Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Qilu Pharmaceutical Atypical Antipsychotic Drugs Product Portfolio Table 82. Qilu Pharmaceutical Recent Development Table 83. Novartis AG Company Information Table 84. Novartis AG Business Overview Table 85. Novartis AG Atypical Antipsychotic Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Novartis AG Atypical Antipsychotic Drugs Product Portfolio Table 87. Novartis AG Recent Development Table 88. Eil Lilly and Company Company Information Table 89. Eil Lilly and Company Business Overview Table 90. Eil Lilly and Company Atypical Antipsychotic Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Eil Lilly and Company Atypical Antipsychotic Drugs Product Portfolio Table 92. Eil Lilly and Company Recent Development Table 93. Pfizer Company Information Table 94. Pfizer Business Overview Table 95. Pfizer Atypical Antipsychotic Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Pfizer Atypical Antipsychotic Drugs Product Portfolio Table 97. Pfizer Recent Development Table 98. GlaxoSmithKline Company Information Table 99. GlaxoSmithKline Business Overview Table 100. GlaxoSmithKline Atypical Antipsychotic Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. GlaxoSmithKline Atypical Antipsychotic Drugs Product Portfolio Table 102. GlaxoSmithKline Recent Development Table 103. AstraZeneca Company Information Table 104. AstraZeneca Business Overview Table 105. AstraZeneca Atypical Antipsychotic Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. AstraZeneca Atypical Antipsychotic Drugs Product Portfolio Table 107. AstraZeneca Recent Development Table 108. Sumitomo Dainippon Pharma Company Information Table 109. Sumitomo Dainippon Pharma Business Overview Table 110. Sumitomo Dainippon Pharma Atypical Antipsychotic Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 111. Sumitomo Dainippon Pharma Atypical Antipsychotic Drugs Product Portfolio Table 112. Sumitomo Dainippon Pharma Recent Development Table 113. Sanis Health Company Information Table 114. Sanis Health Business Overview Table 115. Sanis Health Atypical Antipsychotic Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 116. Sanis Health Atypical Antipsychotic Drugs Product Portfolio Table 117. Sanis Health Recent Development Table 118. Cardinal Health Company Information Table 119. Cardinal Health Business Overview Table 120. Cardinal Health Atypical Antipsychotic Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 121. Cardinal Health Atypical Antipsychotic Drugs Product Portfolio Table 122. Cardinal Health Recent Development Table 123. Bristol-Myers Squibb Company Company Information Table 124. Bristol-Myers Squibb Company Business Overview Table 125. Bristol-Myers Squibb Company Atypical Antipsychotic Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 126. Bristol-Myers Squibb Company Atypical Antipsychotic Drugs Product Portfolio Table 127. Bristol-Myers Squibb Company Recent Development Table 128. Allergan Company Information Table 129. Allergan Business Overview Table 130. Allergan Atypical Antipsychotic Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 131. Allergan Atypical Antipsychotic Drugs Product Portfolio Table 132. Allergan Recent Development Table 133. Key Raw Materials Table 134. Raw Materials Key Suppliers Table 135. Atypical Antipsychotic Drugs Distributors List Table 136. Atypical Antipsychotic Drugs Customers List Table 137. Research Programs/Design for This Report Table 138. Authors List of This Report Table 139. Secondary Sources Table 140. Primary Sources List of Figures Figure 1. Atypical Antipsychotic Drugs Product Image Figure 2. Global Atypical Antipsychotic Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Atypical Antipsychotic Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Atypical Antipsychotic Drugs Sales (2021-2032) & (k units) Figure 5. Global Atypical Antipsychotic Drugs Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Atypical Antipsychotic Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Olanzapine Image Figure 10. Quetiapine Image Figure 11. Risperidone Image Figure 12. Ziprasidone Image Figure 13. Others Image Figure 14. Global Atypical Antipsychotic Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Atypical Antipsychotic Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Atypical Antipsychotic Drugs Sales Volume Share by Type (2021-2032) Figure 17. Global Atypical Antipsychotic Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Atypical Antipsychotic Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Atypical Antipsychotic Drugs Sales Value Share by Type (2021-2032) Figure 20. Schizoaffective Disorder Image Figure 21. Schizophrenia Image Figure 22. Bipolar I Disorder Image Figure 23. Major Depressive Disorder (MDD) Image Figure 24. Global Atypical Antipsychotic Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 25. Global Atypical Antipsychotic Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global Atypical Antipsychotic Drugs Sales Volume Share by Application (2021-2032) Figure 27. Global Atypical Antipsychotic Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Atypical Antipsychotic Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global Atypical Antipsychotic Drugs Sales Value Share by Application (2021-2032) Figure 30. Global Atypical Antipsychotic Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 31. Global Atypical Antipsychotic Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global Atypical Antipsychotic Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global Atypical Antipsychotic Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America Atypical Antipsychotic Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. North America Atypical Antipsychotic Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe Atypical Antipsychotic Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. Europe Atypical Antipsychotic Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific Atypical Antipsychotic Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Atypical Antipsychotic Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America Atypical Antipsychotic Drugs Sales Value (2021-2032) & (US$ Million) Figure 41. South America Atypical Antipsychotic Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa Atypical Antipsychotic Drugs Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa Atypical Antipsychotic Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Atypical Antipsychotic Drugs Value Chain Figure 129. Manufacturing Cost Structure Figure 130. Atypical Antipsychotic Drugs Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • Olanzapine
  • Quetiapine
  • Risperidone
  • Ziprasidone
  • Others
Applications
  • Schizoaffective Disorder
  • Schizophrenia
  • Bipolar I Disorder
  • Major Depressive Disorder (MDD)
Companies covered
  • Sun Pharmaceutical Industries
  • Johnson and Johnson
  • Qilu Pharmaceutical
  • Novartis AG
  • Eil Lilly and Company
  • Pfizer
  • GlaxoSmithKline
  • AstraZeneca
  • Sumitomo Dainippon Pharma
  • Sanis Health
  • Cardinal Health
  • Bristol-Myers Squibb Company
  • Allergan

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Atypical Antipsychotic Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Atypical Antipsychotic Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Atypical Antipsychotic Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Atypical Antipsychotic Drugs Market Dynamics
  1. 2.1 Atypical Antipsychotic Drugs Industry Trends
  2. 2.2 Atypical Antipsychotic Drugs Industry Drivers
  3. 2.3 Atypical Antipsychotic Drugs Industry Opportunities and Challenges
  4. 2.4 Atypical Antipsychotic Drugs Industry Restraints
3 Atypical Antipsychotic Drugs Market by Company
  1. 3.1 Global Atypical Antipsychotic Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Atypical Antipsychotic Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Atypical Antipsychotic Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Atypical Antipsychotic Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Atypical Antipsychotic Drugs Company Ranking (2024-2026)
  6. 3.6 Global Atypical Antipsychotic Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Atypical Antipsychotic Drugs Company Product Type and Application
  8. 3.8 Global Atypical Antipsychotic Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Atypical Antipsychotic Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Atypical Antipsychotic Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Atypical Antipsychotic Drugs Market by Type
  1. 4.1 Atypical Antipsychotic Drugs Type Introduction
  2. 4.1.1 Olanzapine
  3. 4.1.2 Quetiapine
  4. 4.1.3 Risperidone
  5. 4.1.4 Ziprasidone
  6. 4.1.5 Others
  7. 4.2 Global Atypical Antipsychotic Drugs Sales Volume by Type
  8. 4.2.1 Global Atypical Antipsychotic Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Atypical Antipsychotic Drugs Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Atypical Antipsychotic Drugs Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Atypical Antipsychotic Drugs Sales Value by Type
  12. 4.3.1 Global Atypical Antipsychotic Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Atypical Antipsychotic Drugs Sales Value by Type (2021-2032)
  14. 4.3.3 Global Atypical Antipsychotic Drugs Sales Value Share by Type (2021-2032)
5 Atypical Antipsychotic Drugs Market by Application
  1. 5.1 Atypical Antipsychotic Drugs Application Introduction
  2. 5.1.1 Schizoaffective Disorder
  3. 5.1.2 Schizophrenia
  4. 5.1.3 Bipolar I Disorder
  5. 5.1.4 Major Depressive Disorder (MDD)
  6. 5.2 Global Atypical Antipsychotic Drugs Sales Volume by Application
  7. 5.2.1 Global Atypical Antipsychotic Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Atypical Antipsychotic Drugs Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Atypical Antipsychotic Drugs Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Atypical Antipsychotic Drugs Sales Value by Application
  11. 5.3.1 Global Atypical Antipsychotic Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Atypical Antipsychotic Drugs Sales Value by Application (2021-2032)
  13. 5.3.3 Global Atypical Antipsychotic Drugs Sales Value Share by Application (2021-2032)
6 Atypical Antipsychotic Drugs Regional Sales and Value Analysis
  1. 6.1 Global Atypical Antipsychotic Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Atypical Antipsychotic Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Atypical Antipsychotic Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Atypical Antipsychotic Drugs Sales by Region (2027-2032)
  5. 6.3 Global Atypical Antipsychotic Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Atypical Antipsychotic Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Atypical Antipsychotic Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Atypical Antipsychotic Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Atypical Antipsychotic Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Atypical Antipsychotic Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Atypical Antipsychotic Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Atypical Antipsychotic Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Atypical Antipsychotic Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Atypical Antipsychotic Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Atypical Antipsychotic Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Atypical Antipsychotic Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Atypical Antipsychotic Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Atypical Antipsychotic Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Atypical Antipsychotic Drugs Sales Value Share by Country, 2025 VS 2032
7 Atypical Antipsychotic Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Atypical Antipsychotic Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Atypical Antipsychotic Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Atypical Antipsychotic Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Atypical Antipsychotic Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Atypical Antipsychotic Drugs Sales by Country (2027-2032)
  6. 7.4 Global Atypical Antipsychotic Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Atypical Antipsychotic Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Atypical Antipsychotic Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Atypical Antipsychotic Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Atypical Antipsychotic Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Atypical Antipsychotic Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sun Pharmaceutical Industries
  2. 8.1.1 Sun Pharmaceutical Industries Company Information
  3. 8.1.2 Sun Pharmaceutical Industries Business Overview
  4. 8.1.3 Sun Pharmaceutical Industries Atypical Antipsychotic Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Sun Pharmaceutical Industries Atypical Antipsychotic Drugs Product Portfolio
  6. 8.1.5 Sun Pharmaceutical Industries Recent Developments
  7. 8.2 Johnson and Johnson
  8. 8.2.1 Johnson and Johnson Company Information
  9. 8.2.2 Johnson and Johnson Business Overview
  10. 8.2.3 Johnson and Johnson Atypical Antipsychotic Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Johnson and Johnson Atypical Antipsychotic Drugs Product Portfolio
  12. 8.2.5 Johnson and Johnson Recent Developments
  13. 8.3 Qilu Pharmaceutical
  14. 8.3.1 Qilu Pharmaceutical Company Information
  15. 8.3.2 Qilu Pharmaceutical Business Overview
  16. 8.3.3 Qilu Pharmaceutical Atypical Antipsychotic Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Qilu Pharmaceutical Atypical Antipsychotic Drugs Product Portfolio
  18. 8.3.5 Qilu Pharmaceutical Recent Developments
  19. 8.4 Novartis AG
  20. 8.4.1 Novartis AG Company Information
  21. 8.4.2 Novartis AG Business Overview
  22. 8.4.3 Novartis AG Atypical Antipsychotic Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Novartis AG Atypical Antipsychotic Drugs Product Portfolio
  24. 8.4.5 Novartis AG Recent Developments
  25. 8.5 Eil Lilly and Company
  26. 8.5.1 Eil Lilly and Company Company Information
  27. 8.5.2 Eil Lilly and Company Business Overview
  28. 8.5.3 Eil Lilly and Company Atypical Antipsychotic Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Eil Lilly and Company Atypical Antipsychotic Drugs Product Portfolio
  30. 8.5.5 Eil Lilly and Company Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Atypical Antipsychotic Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Atypical Antipsychotic Drugs Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 GlaxoSmithKline
  38. 8.7.1 GlaxoSmithKline Company Information
  39. 8.7.2 GlaxoSmithKline Business Overview
  40. 8.7.3 GlaxoSmithKline Atypical Antipsychotic Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 GlaxoSmithKline Atypical Antipsychotic Drugs Product Portfolio
  42. 8.7.5 GlaxoSmithKline Recent Developments
  43. 8.8 AstraZeneca
  44. 8.8.1 AstraZeneca Company Information
  45. 8.8.2 AstraZeneca Business Overview
  46. 8.8.3 AstraZeneca Atypical Antipsychotic Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 AstraZeneca Atypical Antipsychotic Drugs Product Portfolio
  48. 8.8.5 AstraZeneca Recent Developments
  49. 8.9 Sumitomo Dainippon Pharma
  50. 8.9.1 Sumitomo Dainippon Pharma Company Information
  51. 8.9.2 Sumitomo Dainippon Pharma Business Overview
  52. 8.9.3 Sumitomo Dainippon Pharma Atypical Antipsychotic Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Sumitomo Dainippon Pharma Atypical Antipsychotic Drugs Product Portfolio
  54. 8.9.5 Sumitomo Dainippon Pharma Recent Developments
  55. 8.10 Sanis Health
  56. 8.10.1 Sanis Health Company Information
  57. 8.10.2 Sanis Health Business Overview
  58. 8.10.3 Sanis Health Atypical Antipsychotic Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Sanis Health Atypical Antipsychotic Drugs Product Portfolio
  60. 8.10.5 Sanis Health Recent Developments
  61. 8.11 Cardinal Health
  62. 8.11.1 Cardinal Health Company Information
  63. 8.11.2 Cardinal Health Business Overview
  64. 8.11.3 Cardinal Health Atypical Antipsychotic Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Cardinal Health Atypical Antipsychotic Drugs Product Portfolio
  66. 8.11.5 Cardinal Health Recent Developments
  67. 8.12 Bristol-Myers Squibb Company
  68. 8.12.1 Bristol-Myers Squibb Company Company Information
  69. 8.12.2 Bristol-Myers Squibb Company Business Overview
  70. 8.12.3 Bristol-Myers Squibb Company Atypical Antipsychotic Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Bristol-Myers Squibb Company Atypical Antipsychotic Drugs Product Portfolio
  72. 8.12.5 Bristol-Myers Squibb Company Recent Developments
  73. 8.13 Allergan
  74. 8.13.1 Allergan Company Information
  75. 8.13.2 Allergan Business Overview
  76. 8.13.3 Allergan Atypical Antipsychotic Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Allergan Atypical Antipsychotic Drugs Product Portfolio
  78. 8.13.5 Allergan Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Atypical Antipsychotic Drugs Value Chain Analysis
  2. 9.1.1 Atypical Antipsychotic Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Atypical Antipsychotic Drugs Sales Mode & Process
  6. 9.2 Atypical Antipsychotic Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Atypical Antipsychotic Drugs Distributors
  9. 9.2.3 Atypical Antipsychotic Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst